Thus, only endocrine receptor (ER)-positive breast cancers benefit from endocrine therapy, whereas cytotoxic chemotherapy, without and with anti-HER2 agents, has maximum efficacy in triple-negative and HER2-positive subtypes, respectively. The gene discussed is ESR1; the disease is breast cancer.